China guideline for liver cancer screening (2022, Beijing)
10.3969/j.issn.1001-5256.2022.08.007
- VernacularTitle:中国人群肝癌筛查指南(2022，北京)
- Author:
Jie HE
1
;
Wanqing CHEN
1
;
Hongbing SHEN
2
;
Ni LI
1
;
Chunfeng QU
1
;
Jufang SHI
1
;
Feng SUN
3
;
Jing JIANG
4
;
Guangwen CAO
5
;
Guihua ZHUANG
6
;
Ji PENG
7
Author Information
1. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
2. School of Public Health, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing 211166, China
3. School of Public Health, Peking University, Beijing 100191, China
4. The First Hospital of Jilin University, Changchun 130021, China
5. Department of Epidemiology, Naval Medical University, Shanghai 200433, China
6. School of Public Health, Xi′an Jiaotong University Health Science Center, Xi′an 710061, China
7. Shenzhen Centre for Chronic Disease Control, Shenzhen 518020, China
- Collective Name:;
- Publication Type:Guidelines
- Keywords:
Liver Neoplasms;
Screening;
Surveillance;
Guideline;
China
- From:
Journal of Clinical Hepatology
2022;38(8):1739-1772
- CountryChina
- Language:Chinese
-
Abstract:
In China, the survival rate of liver cancer remains low while the mortality rate is high. Effectively reducing the burden of liver cancer is still a major challenge in the field of public health and chronic disease prevention in the Chinese population. Optimizing screening strategies for liver cancer remains a profound approach to secondary prevention worthy of continuous exploration. To address this pressing issue, the Bureau of Disease Control and Prevention of the National Health Commission commissioned this guideline. The National Cancer Center of China initiated the guideline development and convened a multidisciplinary expert panel and working groups. Following the World Health Organization Handbook for Guideline Development, this guideline integrated the most up-to-date evidence of liver cancer screening, China's national conditions, and existing practical experience in liver cancer screening. Evidence-based recommendations on the target population, screening technologies, surveillance strategies, and other key points across the process of liver cancer screening and surveillance management were provided. This guideline would help standardize the practice of liver cancer screening in China.
